Cargando…

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting

AIM: To assess the efficacy and safety of combined directly acting antivirals (DAAs) for the treatment of Chinese chronic hepatitis C (CHC) patients in a real-world setting. METHODS: Hospitalized CHC patients who were treated with DAAs at Peking University First Hospital between January 2015 and Dec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jian-Hong, Zeng, Zheng, Zhang, Xia-Xia, Zhang, Yu, Zhang, Ren-Wen, Wang, Shuai, Wu, Chi-Hong, Yu, Min, Liu, Dan, Xi, Hong-Li, Zhou, Yi-Xing, An, Yao-Yu, Xu, Xiao-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473126/ https://www.ncbi.nlm.nih.gov/pubmed/28652660 http://dx.doi.org/10.3748/wjg.v23.i22.4072

Ejemplares similares

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China
por: Yang, Ying, et al.
Publicado: (2019)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms
por: Nardelli, Silvia, et al.
Publicado: (2019)

Contemporary characteristics, management, and outcomes of patients hospitalized for atrial fibrillation in China: results from the real-world study of Chinese atrial fibrillation registry
por: Zhao, Qing-Yan, et al.
Publicado: (2020)

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients
por: Luo, Hao, et al.
Publicado: (2019)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Chang, Kao-Chi, et al.
Publicado: (2021)

Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals
por: Lee, Shou-Wu, et al.
Publicado: (2018)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study
por: Ferrarese, Alberto, et al.
Publicado: (2018)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
por: Ramos, Huascar, et al.
Publicado: (2017)

Hepatitis D virus dual-infection among Chinese hepatitis B patient related to hepatitis B surface antigen, hepatitis B virus DNA and age
por: Zi, Jun, et al.
Publicado: (2023)

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
por: Damiani, Giovanni, et al.
Publicado: (2018)

Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus
por: Rupp, Christian, et al.
Publicado: (2018)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting
por: Chen, Hongyu, et al.
Publicado: (2022)

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
por: Kang, Yeo Wool, et al.
Publicado: (2021)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
por: Kieran, Jennifer Ann, et al.
Publicado: (2015)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
por: Sarıgül Yıldırım, Figen, et al.
Publicado: (2022)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2020)

Connexin-Dependent Transfer of cGAMP to Phagocytes Modulates Antiviral Responses
por: Pépin, Geneviève, et al.
Publicado: (2020)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance
por: Loo, Nicole, et al.
Publicado: (2019)

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
por: Lee, Sun Hee, et al.
Publicado: (2020)

Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea
por: Ghebremeskel, Ghirmay Ghebrekidan, et al.
Publicado: (2023)

Topoisomerase 1 Inhibition Promotes Cyclic GMP-AMP Synthase-Dependent Antiviral Responses
por: Pépin, Geneviève, et al.
Publicado: (2017)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
por: Wang, Yadong, et al.
Publicado: (2022)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
por: Mei, Yong-yu, et al.
Publicado: (2020)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g33bqijet21bvddu76b1p4rmk5